Regeneron Pharmaceuticals

The provided content does not contain any text to summarize.

Odronextamab showed 100% complete response in untreated follicular lymphoma, 48% objective response in DLBCL post-CAR-T, and 77% complete response in relapsed/refractory marginal zone lymphoma. EU approval secured; U.S. resubmission planned for 2025.

SkyQuest projects the cancer monoclonal antibodies market to reach USD 337.92 billion by 2031, with a CAGR of 18.4% (2024-2031). Factors driving growth include high cancer incidence, biotechnology advancements, and rising use of combination therapies and biosimilars. North America leads due to robust R&D investments, while blood cancer treatments dominate the market. Key players include AbbVie, Amgen, Merck, and Bristol-Myers Squibb.

New data for odronextamab presented at ASH 2024 show potential in earlier lines of treatment and additional types of lymphoma, including complete responses in follicular lymphoma and durable responses in diffuse large B-cell lymphoma progressing after CAR-T therapy.

Loncastuximab tesirine (Zynlonta) combined with rituximab showed a 97% response rate at 12 weeks in a phase II trial for relapsed or refractory follicular lymphoma, with 67% achieving complete response. The combination demonstrated high progression-free and overall survival rates, suggesting it as a promising treatment option for second-line and later follicular lymphoma.

The Oncology Market is critical in global healthcare, driven by cancer prevalence, technological advancements, and strategic collaborations. Key players like Daiichi Sankyo, Bayer AG, and others innovate in diagnostics, treatments, and precision medicine. Market growth is fueled by R&D investments, sustainability focus, and consumer awareness. Challenges include regulatory constraints and talent shortages. Technological integrations like AI and IoT enhance patient care and operational efficiency.

Phase 3 trial data showed poze-cemdi, a first-in-class combination treatment, helped more PNH patients achieve and maintain LDH control compared to ravulizumab, with 96% achieving adequate LDH control and 93% achieving normalization.

Switch Market flag for country-specific data. Right-click on chart for more options. Use up/down arrows to navigate symbols.